Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-091366
Filing Date
2025-09-18
Accepted
2025-09-18 18:48:08
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5210
2 EXHIBIT 24.1 tm2526490d1_ex24-1.htm EX-24.1 5531
  Complete submission text file 0001104659-25-091366.txt   12184
Mailing Address 2934 OESTRICK LANE AUSTIN TX 78733
Business Address
DEJORIA JOHN PAUL (Filed by) CIK: 0000897610 (see all company filings)

Type: SCHEDULE 13G

Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Subject) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-95236 | Film No.: 251324607
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)